Abcam, ab263190, Human ERI3 knockout HeLa cell lysate

Size: 1Kit
ERI3 KO cell lysate available now. KO validated by. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 279 bp deletion in exon1.
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 279 bp deletion in exon1.,
Disease:Adenocarcinoma

Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-ERI3, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The ERI3 protein also known as EC-RNA Interacting Protein 3 functions mechanistically in the processing of RNA. This protein has a molecular mass of approximately 72 kDa. ERI3 expression occurs across several tissues with notable presence in the liver and kidneys. Its role in RNA processing makes it integral to various cellular processes that require accurate RNA management.
Biological function summary
ERI3 decapsulates mRNA influencing mRNA stability and turnover. This function positions ERI3 as essential in mRNA decay mechanisms. ERI3 doesn't work in isolation; it forms part of a multi-protein complex involved in mRNA decay and RNA processing activities. Studies suggest that it interacts directly with other key proteins in these complexes contributing to its biological significance.
Pathways
ERI3 plays a role in RNA degradation and nonsense-mediated mRNA decay pathways. It contributes to these pathways by interacting with proteins such as DCP2 and XRN1 which are important for mRNA turnover. This involvement ensures that cells maintain their mRNA levels and quality affecting overall protein synthesis necessary for cellular function.
ERI3 shows a connection to liver cancer where its dysregulation impacts RNA decay processes linked to tumorigenesis. Another disorder associated with ERI3 is hereditary hemochromatosis although the connection is still under exploration. Within liver cancer the protein's relationship with DCP2 may influence disease progression highlighting ERI3's potential as a therapeutic target or biomarker.